{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T15:04:24Z","timestamp":1785942264082,"version":"3.56.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1097\/icu.0b013e328010ab35","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T05:20:36Z","timestamp":1161753636000},"page":"567-573","source":"Crossref","is-referenced-by-count":22,"title":["Interferon therapy for ocular disease"],"prefix":"10.1097","volume":"17","author":[{"given":"Friederike","family":"Mackensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Max","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias D","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-15-20210206","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.0105-2896.2005.00252.x","article-title":"Interferons as pathogenic effectors in autoimmunity","volume":"204","author":"Baccala","year":"2005","journal-title":"Immunol Rev"},{"issue":"Suppl 3","key":"R2-15-20210206","first-page":"iii3","article-title":"History of modern multiple sclerosis therapy","volume":"252","author":"Lublin","year":"2005","journal-title":"J Neurol"},{"key":"R3-15-20210206","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.immunol.23.021704.115843","article-title":"Type I interferons (alpha\/beta) in immunity and autoimmunity","volume":"23","author":"Theofilopoulos","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"R4-15-20210206","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.71.4.565","article-title":"Interferon-alpha as an immunotherapeutic protein","volume":"71","author":"Brassard","year":"2002","journal-title":"J Leukoc Biol"},{"key":"R5-15-20210206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2005.08.029","article-title":"Interferon and the central nervous system","volume":"523","author":"Dafny","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"R6-15-20210206","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/art.1780250407","article-title":"Serum interferon levels in patients with systemic lupus erythematosus","volume":"25","author":"Ytterberg","year":"1982","journal-title":"Arthritis Rheum"},{"key":"R7-15-20210206","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1167\/iovs.05-0836","article-title":"Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis","volume":"47","author":"Takase","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-15-20210206","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ana.410410309","article-title":"Genetic predisposition to multiple sclerosis as revealed by immunoprinting","volume":"41","author":"Epplen","year":"1997","journal-title":"Ann Neurol"},{"key":"R9-15-20210206","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/sj.gene.6363634","article-title":"The interferon gene cluster: a candidate region for MS predisposition?","volume":"1","author":"Miterski","year":"1999","journal-title":"Genes Immun"},{"key":"R10-15-20210206","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1136\/bjo.2004.057620","article-title":"Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom?","volume":"89","author":"Stanford","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R11-15-20210206","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00439-004-1099-5","article-title":"Association between IFNA genotype and the risk of sarcoidosis","volume":"114","author":"Akahoshi","year":"2004","journal-title":"Hum Genet"},{"key":"R12-15-20210206","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1046\/j.0007-0963.2001.04570.x","article-title":"Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases","volume":"146","author":"Cogrel","year":"2002","journal-title":"Br J Dermatol"},{"key":"R13-15-20210206","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000057631","article-title":"Immune-mediated complications during interferon therapy in hematological patients","volume":"107","author":"Raanani","year":"2002","journal-title":"Acta Haematol"},{"key":"R14-15-20210206","first-page":"S20","article-title":"Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcet's disease treated with human recombinant interferon-alpha2a: results of an open study and review of the literature","volume":"23","author":"Kotter","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R15-15-20210206","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/cncr.21760","article-title":"Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma","volume":"106","author":"Verma","year":"2006","journal-title":"Cancer"},{"key":"R16-15-20210206","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjmed.2005.06.021","article-title":"Hepatitis B virus infection: current status","volume":"118","author":"Ocama","year":"2005","journal-title":"Am J Med"},{"key":"R17-15-20210206","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data","volume":"68","author":"Glue","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R18-15-20210206","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/jhep.2001.26371","article-title":"A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C","volume":"34","author":"Lindsay","year":"2001","journal-title":"Hepatology"},{"key":"R19-15-20210206","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2005.08.003","article-title":"Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial","volume":"239","author":"Panitch","year":"2005","journal-title":"J Neurol Sci"},{"key":"R20-15-20210206","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/WNL.51.3.682","article-title":"Interferon beta in the treatment of multiple sclerosis: mechanisms of action","volume":"51","author":"Yong","year":"1998","journal-title":"Neurology"},{"key":"R21-15-20210206","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/135245859700300609","article-title":"Mechanisms of interferon beta action in multiple sclerosis","volume":"3","author":"Dhib-Jalbut","year":"1997","journal-title":"Mult Scler"},{"key":"R22-15-20210206","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1212\/WNL.45.2.367","article-title":"Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes","volume":"45","author":"Satoh","year":"1995","journal-title":"Neurology"},{"key":"R23-15-20210206","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0165-5728(95)00072-A","article-title":"Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells","volume":"61","author":"Jiang","year":"1995","journal-title":"J Neuroimmunol"},{"key":"R24-15-20210206","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/10623320390272299","article-title":"Interferon (IFN)-beta 1a and IFN-beta 1b block IFN-gamma-induced disintegration of endothelial junction integrity and barrier","volume":"10","author":"Minagar","year":"2003","journal-title":"Endothelium"},{"key":"R25-15-20210206","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","article-title":"Interferon as a treatment for uveitis associated with multiple sclerosis","volume":"89","author":"Becker","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"R26-15-20210206","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/jnnp.2004.054635","article-title":"Depression in multiple sclerosis: a review","volume":"76","author":"Siegert","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R27-15-20210206","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"R28-15-20210206","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1097\/00002030-200409030-00009","article-title":"Serious ophthalmic pathology compromising vision in HCV\/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin","volume":"18","author":"Farel","year":"2004","journal-title":"AIDS"},{"key":"R29-15-20210206","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jhep.2005.07.026","article-title":"Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis","volume":"44","author":"D'Alteroche","year":"2006","journal-title":"J Hepatol"},{"key":"R30-15-20210206","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/135965350601100403","article-title":"Vascular ophthalmological side effects associated with antiviral therapy for chronic hepatitis C are related to vascular endothelial growth factor levels","volume":"11","author":"Andrade","year":"2006","journal-title":"Antivir Ther"},{"key":"R31-15-20210206","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clim.2004.01.008","article-title":"Interferon alpha: a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity","volume":"111","author":"Devendra","year":"2004","journal-title":"Clin Immunol"},{"key":"R32-15-20210206","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1089\/10799900260475669","article-title":"Ingested type I interferon: a potential treatment for autoimmunity","volume":"22","author":"Brod","year":"2002","journal-title":"J Interferon Cytokine Res"},{"key":"R34-15-20210206","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/archopht.1984.01040030432018","article-title":"Combination therapy for dendritic keratitis: high-titer alpha-interferon and trifluridine","volume":"102","author":"Sundmacher","year":"1984","journal-title":"Arch Ophthalmol"},{"key":"R35-15-20210206","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF00414939","article-title":"The effect of human leukocyte interferon (HIF) on experimental viral keratitis in monkeys (author's transl) [in German]","volume":"195","author":"Sundmacher","year":"1975","journal-title":"Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"R36-15-20210206","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1055\/s-2008-1046070","article-title":"Local prevention with interferon of \u201cepidemic\u201d conjunctivitis caused by a currently unidentifiable virus [in German]","volume":"199","author":"Rossa","year":"1991","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R37-15-20210206","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s00347-005-1249-8","article-title":"Adjuvant topical interferon-alpha-2b treatment in epithelial tumors of the ocular surface","volume":"103","author":"Fuchsluger","year":"2006","journal-title":"Ophthalmologe"},{"key":"R38-15-20210206","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ophtha.2004.01.034","article-title":"Treatment of recurrent corneal and conjunctival intraepithelial neoplasia with topical interferon alfa 2b","volume":"111","author":"Boehm","year":"2004","journal-title":"Ophthalmology"},{"key":"R39-15-20210206","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00003226-200201000-00003","article-title":"Regression of presumed primary conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b","volume":"21","author":"Schechter","year":"2002","journal-title":"Cornea"},{"key":"R40-15-20210206","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0161-6420(01)00577-2","article-title":"Treatment of conjunctival and corneal intraepithelial neoplasia with topical interferon alpha-2b","volume":"108","author":"Karp","year":"2001","journal-title":"Ophthalmology"},{"key":"R41-15-20210206","first-page":"185","article-title":"Intravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration: a pilot study","volume":"32","author":"Kertes","year":"1997","journal-title":"Can J Ophthalmol"},{"key":"R42-15-20210206","first-page":"355","article-title":"Toxicity of intravitreal interferon alpha-2b in the rabbit","volume":"30","author":"Kertes","year":"1995","journal-title":"Can J Ophthalmol"},{"key":"R43-15-20210206","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","article-title":"Interferon alfa-2a: a new treatment option for longlasting refractory cystoid macular edema in uveitis? A pilot study","volume":"26","author":"Deuter","year":"2006","journal-title":"Retina"},{"key":"R44-15-20210206","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R45-15-20210206","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"R46-15-20210206","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00041327-200112000-00013","article-title":"The Controlled High Risk Avonex Multiple Sclerosis Trial (CHAMPS Study)","volume":"21","author":"Galetta","year":"2001","journal-title":"J Neuroophthalmol"},{"key":"R47-15-20210206","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0002-9394(01)01209-0","article-title":"Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.","volume":"132","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"R48-15-20210206","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Behcet's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"R49-15-20210206","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","article-title":"Effectiveness of cyclosporin therapy for Behcet's disease","volume":"28","author":"Nussenblatt","year":"1985","journal-title":"Arthritis Rheum"},{"key":"R50-15-20210206","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Behcet's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R51-15-20210206","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00006231-199403000-00011","article-title":"The role of quantitative 99Tcm-glucoheptonate scintigraphy in the evaluation of acute uveitis in patients with Behcet's disease","volume":"15","author":"Mudun","year":"1994","journal-title":"Nucl Med Commun"},{"key":"R52-15-20210206","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/art.21231","article-title":"Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial","volume":"52","author":"Tugal-Tutkun","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R53-15-20210206","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00407749","article-title":"Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon","volume":"278","author":"Tsambaos","year":"1986","journal-title":"Arch Dermatol Res"},{"key":"R54-15-20210206","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(94)92549-6","article-title":"Interferon-alpha 2b for refractory ocular Behcet's disease","volume":"343","author":"Feron","year":"1994","journal-title":"Lancet"},{"key":"R55-15-20210206","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"R56-15-20210206","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Behcet's disease: an open study","volume":"62","author":"Calguneri","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"R57-15-20210206","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"R58-15-20210206","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/0-306-48382-3_103","article-title":"Interferon alfa-2a in the treatment of ocular Adamantiades-Behcet's disease","volume":"528","author":"Krause","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"R59-15-20210206","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archopht.1997.01100160035005","article-title":"Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration: results of a prospective randomized placebo-controlled clinical trial.","volume":"115","year":"1997","journal-title":"Arch Ophthalmol"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICU.0b013e328010ab35","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:26:09Z","timestamp":1785939969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00055735-200612000-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0b013e328010ab35","relation":{},"ISSN":["1040-8738"],"issn-type":[{"value":"1040-8738","type":"print"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}